Last updated: July 27, 2026
Insys Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc., case number 1:18-cv-01308, is a U.S. federal patent dispute filed in 2018. The matter centers on Insys’ intellectual property tied to its fentanyl product franchise and Teva’s effort to market a competing product under FDA pathways that typically trigger Orange Book-based patent litigation. The litigation’s practical effect is to determine whether Teva can launch during the pendency of asserted patents or after a stay lifts, and what carve-outs or licensing terms apply for any agreed “design-around” or amended labeling/route changes.
What happened in Insys Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc., 1:18-cv-01308?
Core dispute: Insys sued Teva for patent infringement in a Hatch-Waxman-style framework tied to Insys’ FDA-listed patents, with Teva’s generic (or generic-like) filing timing creating an automatic litigation lever.
Case timing and procedural milestones
Key dates typically include:
- Complaint filing: 2018 (case number 1:18-cv-01308).
- Infringement claims: Insys alleged that Teva’s proposed product infringed one or more claims of asserted Orange Book-listed patents.
- Teva response: Teva generally denies infringement and challenges validity (anticipation/obviousness, indefiniteness, written description/enablement, and prosecution-history estoppel defenses are typical).
- Court actions affecting launch risk: Markman proceedings, motion practice (pleadings, dismissal, summary judgment), and any stipulation or stay tied to related proceedings.
What the lawsuit is “about” in functional terms
In high-stakes generic-entry cases, the litigation’s controllables usually reduce to:
- Which patents are asserted (drug substance, formulations, manufacturing, and method-of-use).
- Whether Teva’s product is “covered” by those claims.
- Whether asserted patents survive validity challenges.
- Whether FDA approval timing is held back by the litigation/automatic stay and settlement terms (if any).
Which patents and Orange Book listings are at issue in Insys v. Teva (1:18-cv-01308)?
Answer in practice: The asserted patents are almost always selected from Orange Book listings for the reference listed drug (RLD), with claims directed to either:
- the formulation (e.g., proprietary compositions, film/tablet/solvent systems),
- pharmaceutical development (release kinetics, particle size, stabilizers),
- methods of use (indication-specific claims), or
- manufacturing (process claims that limit how the generic is made).
How to map the patent estate to infringement hooks
In Insys’ fentanyl-related portfolio, infringement theories in comparable cases generally track:
- Composition/formulation patents: if Teva’s proposed formulation overlaps claim features (excipients, ratios, coating technologies, or stability system),
- Dosing regimen claims: if method-of-use language is part of the asserted set, and Teva’s proposed labeling matches,
- Manufacturing-process claims: if claim elements tie to specific manufacturing steps, mixing conditions, or drying/processing parameters.
Common Teva defense patterns
In generic patent cases, Teva typically attacks:
- Claim construction (narrowing or requiring specific claim features),
- Non-infringement (no literal infringement and no doctrine-of-equivalents overlap),
- Invalidity using prior art that predates the priority date and routine obviousness combinations,
- Procedural defects (incomplete pleading, failure to state infringement with particularity, or improper joinder).
What does the case posture suggest for Teva’s generic launch risk?
Answer: In a Hatch-Waxman infringement posture, launch risk hinges on three variables:
- Whether an asserted patent is still in force for the relevant Orange Book-listed term,
- Whether the court finds infringement (or denies summary judgment and sets trial),
- Whether validity is sustained or claims are narrowed/invalidated.
Injunction exposure
If Insys secures a favorable infringement ruling and validity survives, Teva faces:
- prohibition on launch for the covered product until expiration or final resolution,
- potential stipulated entry dates (if settlement),
- potential workarounds that re-design formulation or labeling to avoid claim elements.
Stay mechanics
The stay usually blocks entry if Teva filed an ANDA and triggered litigation on listed patents. Even when FDA approval is possible, actual launch is typically delayed until:
- the litigation concludes,
- a partial stay ends due to specific patent outcomes, or
- a settlement permits earlier limited entry.
How does Insys v. Teva compare with other fentanyl patent litigations?
Answer: Fentanyl franchise litigations commonly involve overlapping issues: formulation claim coverage, method-of-use labeling triggers, and invalidity arguments built around early fentanyl delivery system publications.
Typical claim clusters in this therapeutic area
- Drug delivery and release control: “fast onset” and absorption-related claim elements.
- Stability and handling: excipient choices and physical/chemical stability conditions.
- Administration mechanics: device-related features or dosing workflow.
- Labeling-bound method-of-use: if method claims require a patient population or administration timing.
What are the likely infringement and validity issues the court would analyze in 1:18-cv-01308?
Infringement: what must be proven
Insys must show that Teva’s proposed product:
- meets every limitation of each asserted claim (literal infringement), or
- is equivalent under the doctrine-of-equivalents framework without running into prosecution-history limits.
Validity: what usually drives outcomes
Courts frequently focus on:
- §102 anticipation (single reference invalidates),
- §103 obviousness (combinations that a skilled artisan would make),
- §112 requirements (written description, enablement, and definiteness),
- prior art scope and whether the cited art is enabling.
What happens if the court construes claims narrowly for Teva?
Answer: Narrow construction often produces faster non-infringement outcomes when the proposed generic does not match a specific parameter (e.g., exact excipient class, specific particle size, a defined process step, or a strict release profile threshold). In practice, Insys then either:
- drops claims at summary judgment, or
- pursues a narrower set to trial.
What settlement terms typically arise in Insys-style ANDA patent cases?
Answer: Where a settlement occurs, it usually takes the form of:
- Agreed entry date (potentially earlier than full expiration),
- royalty or license structure tied to sales,
- carve-outs for specific strengths/dosage forms,
- stipulations that end injunction exposure after a date.
If there is no settlement, the expected path is trial and appeal, extending the timeline and increasing litigation spend for both sides.
How does the litigation affect FDA Orange Book status and exclusivity timelines?
Answer: The lawsuit affects launch timing more than it affects Orange Book listing itself. If patents remain listed, FDA maintains patent-based exclusivity and eligibility constraints:
- Teva’s ability to commercialize depends on the outcome of the litigation tied to those patents and any settlement/entry permission.
Featured snippet-ready bottom line
- If asserted patents are upheld as valid and infringed, Teva generally cannot launch until expiration.
- If patents are found invalid or not infringed, Teva’s path to launch accelerates once any remaining stays or remaining asserted patents are cleared.
What generic entry risks exist for Teva beyond this specific case?
Answer: Even with favorable outcomes in one case, entry risk remains if:
- other Insys patents covering the same RLD remain asserted in parallel actions,
- other defendants or separate cases address different patent subsets,
- labeling changes still inadvertently trigger method-of-use coverage.
In fentanyl product categories, parallel patent actions are common because patent estates often span formulation, method of use, and manufacturing.
Key timeline (case-driven decision points)
| Phase |
What matters |
Typical impact on Teva launch |
| Complaint and initial pleadings (2018) |
Asserted patent list and infringement charts |
Sets the automatic litigation framework |
| Claim construction / Markman |
Narrows claim scope and defines infringement “match” |
Often determines whether non-infringement wins early |
| Validity motions and summary judgment |
Invalidity/dispositive rulings |
Can trigger “entry if no remaining barriers” |
| Trial and/or settlement |
Final infringement/validity outcomes or agreed entry date |
Controls whether launch occurs during appeal or after |
Case impact assessment for business planning
For Insys
The litigation is strategically aimed at:
- protecting formulation/method coverage that prevents generic market entry,
- reducing the chance of design-around by forcing Teva to litigate multiple claim limitations,
- preserving leverage for licensing or settlement.
For Teva
The risk model is:
- Teva cannot launch if the court upholds infringement and validity on remaining asserted patents.
- Teva’s practical design-around options depend on claim scope from claim construction.
- Even if some patents fall, “any one” remaining enforceable barrier can delay entry.
Key Takeaways
- Insys v. Teva (1:18-cv-01308) is a patent infringement dispute tied to FDA-listed IP that governs whether Teva can commercialize a competing product during the litigation and stay window.
- Outcome drivers are the asserted Orange Book-linked patents, claim construction, and validity rulings.
- Business impact centers on whether Teva’s proposed product is found to infringe and whether asserted claims survive invalidity challenges, determining launch timing or settlement-based entry dates.
FAQs
- What determines whether Teva can launch during an ongoing Insys v. Teva appeal?
- Which claim types (formulation, method of use, manufacturing) most often decide generic entry in fentanyl patent disputes?
- How do claim construction results typically change infringement outcomes in Hatch-Waxman cases?
- What settlement structures are most common in ANDA patent litigations involving Orange Book-listed patents?
- Can a design-around by a generic avoid infringement without affecting FDA approval timing?
References (APA)
- Insys Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc., No. 1:18-cv-01308 (U.S. Dist. Ct. 2018).
